title: Dietary component p-coumaric acid suppresses monosodium urate crystal-induced inflammation in rats.
abstract: OBJECTIVE
  This study was conducted to evaluate the effect of p-Coumaric acid, a common dietary phenol, on monosodium urate crystal-induced inflammation in rats-an experimental model for acute gouty arthritis.
  
  
  METHODS
  Paw edema, levels/activities of lysosomal enzymes, lipid peroxidation, enzymic antioxidants and a histopathological examination of ankle joints were evaluated in control and monosodium urate crystal-induced inflamed rats. Further, an acetic acid-induced writhing test and tail immersion test were employed to screen for analgesic effects, yeast-induced pyrexia was used to test for antipyretic effects, and gastric ulceration was used to evaluate ulcerogenic effects.
  
  
  RESULTS
  A significant increase in paw edema, lysosomal enzyme activity and lipid peroxidation levels was observed in monosodium urate crystal-induced rats, whereas activities of enzymic antioxidants were found to be decreased when compared to control rats. Nevertheless, treatment with p-Coumaric acid (100 mg/kg b.wt) significantly reverted the altered physical and biochemical parameters back to near normal levels, as evidenced by the histopathology of the ankle joints. In addition, p-Coumaric acid also exhibited potent analgesic and antipyretic effects devoid of any adverse impact on gastric mucosa.
  
  
  CONCLUSIONS
  The results of this study reveal the potential anti-inflammatory effect of p-Coumaric acid against monosodium urate crystal-induced inflammation in rats.
authors: Immunopathology Lab, School of Bio Sciences and Technology, VIT University, Vellore, 632 014 Tamil Nadu, India.
authors: Samuel Joshua
authors: SJ
authors: Pragasam
authors: Mahaboobkhan
authors: M
authors: Rasool
mesh_terms: D019342:Acetic Acid; D000135:Acid Phosphatase / Q000378:metabolism; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D058633:Antipyretics / Q000494:pharmacology / Q000627:therapeutic use*; D002374:Catalase / Q000378:metabolism; D003373:Coumaric Acids / Q000494:pharmacology / Q000627:therapeutic use*; D004032:Diet; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy; D005966:Glucuronidase / Q000378:metabolism; D006596:Hexosaminidases / Q000378:metabolism; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015227:Lipid Peroxidation; D008297:Male; D010146:Pain / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D011422:Propionates; D051381:Rats; D017208:Rats, Wistar; D012441:Saccharomyces cerevisiae; D013482:Superoxide Dismutase / Q000378:metabolism; D014527:Uric Acid; D001617:beta-Glucosidase / Q000378:metabolism
chemical_list: D000700:Analgesics; D000893:Anti-Inflammatory Agents; D058633:Antipyretics; D003373:Coumaric Acids; D011422:Propionates; D014527:Uric Acid; D002374:Catalase; D013482:Superoxide Dismutase; D000135:Acid Phosphatase; D006596:Hexosaminidases; D001617:beta-Glucosidase; D005966:Glucuronidase; C495469:p-coumaric acid; D019342:Acetic Acid